Studies mood changes in people with bladder cancer receiving BCG
Observes mood changes in adults with non-muscle invasive bladder cancer receiving BCG treatment.
Plain-language title generated from the registry record
Registry title: Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Key facts
- Where
- Washington D.C., United StatesSee the site
Where in United States
- Sibley Memorial HospitalWashington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT05672615
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer receiving intravesical treatments are eligible to participate in this study. Participation involves providing research blood and urine samples prior to the start of treatment and throughout the treatment course. The study team will also collect participant's medical history and clinical information. Participants will be asked to complete questionnaires and daily mood diaries.Read full original descriptionShow less
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With Bacillus Calmete-Guerin
The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer receiving intravesical treatments are eligible to participate in this study. Participation involves providing research blood and urine samples prior to the start of treatment and throughout the treatment course. The study team will also collect participant's medical history and clinical information. Participants will be asked to complete questionnaires and daily mood diaries.
Inclusion: Subjects with a pathologically confirmed non-muscle invasive bladder cancer; Age ≥ 18 years old; Ability to understand and willingness to sign a written informed consent document.
Exclusion: Patients that are not candidates for intravesical treatment due to the nature of their disease, such as variant histology or progressive disease after a prior course of intravesical treatment; Patients who are pregnant.